Kintara Therapeutics, Inc. (KTRA)

Market Cap	6.62M
Revenue (ttm)	n/a
Net Income (ttm)	-19.22M
Shares Out	1.68M
EPS (ttm)	-14.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,029
Open	3.67
Previous Close	3.64
Day's Range	3.67 - 3.95
52-Week Range	2.80 - 42.00
Beta	1.00
Analysts	Sell
Price Target	153.00 (+3,773.42%)
Earnings Date	Feb 14, 2023

About KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: KTRA

Analyst Forecast

According to 7 analysts, the average rating for KTRA stock is "Sell." The 12-month stock price forecast is $153.0, which is an increase of 3,773.42% from the latest price.

Price Target

$153.0

(3,773.42% upside)

Analyst Consensus: Sell